CRLBF - Cresco Labs Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
6.93
-0.27 (-3.76%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close7.20
Open7.15
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.75 - 7.30
52 Week Range0.81 - 40.63
Volume657,430
Avg. Volume239,473
Market Cap783.12M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.48
Trade prices are not sourced from all markets
  • Cresco Labs Shares Down as Regulatory Uncertainty Weighs
    TipRanks

    Cresco Labs Shares Down as Regulatory Uncertainty Weighs

    The U.S. multi-state operator (MSO) cannabis sector has taken severe stock hits in the last few months. Companies like Cresco Labs (CRLBF) have generally all hit financial goals, but the market has shaken off the positive developments due to a lack of progress of closing key mergers and federal approval of cannabis. The stock is down sharply as the company stacks another merger on top of other large pending deals.Another MergerThe stock slumped to nearly $7 following a rally above $13 just back in April. The nearly 45% loss is in line with most domestic MSOs as the excitement over large-scale acquisitions has faded with none of the deals closing in a timely manner.Cresco Labs announced the acquisition of Tryke of $282.5 million. Tryke operates six retail stores in Arizona and Nevada under the Reef Dispensary brand.On the surface, the deal appears solid with the company generating 2018 revenues of $70.4 million and an impressive EBITDA of $24.6 million. A deal costing 12x trailing EBITDA in a fast-growing sector is typically encouraged.The problem here is that Cresco Labs has several pending major acquisitions and the market is naturally concerned the regulators will balk at these MSOs gaining too much scale.The company announced the acquisition of Origin House on April 1 in a deal promoted as the largest ever public company deal in the U.S. cannabis sector. The deal had a listed value of C$1.1 billion or roughly $850 million at the time. Origin House has a listed market value of only $440 million now as investors lose interest in the sector and the deal closing.The market clearly has concerns about the deal closing with Origin House trading at only $5.50 now. The company originally forecast the deal closing by the end of June and the date was recently pushed out as closing after the waiting period for HSR expires on October 17. The market isn’t comforted by the ongoing delay.In addition, VidaCann hasn’t closed adding more regulatory uncertainty. The pending acquisition target expects to have 20 stores open in Florida by the end of 2019 to greatly expand on the market opportunity for Cresco Labs. The Tryke merger makes for three relatively large-scale deals pending.Focus On The FutureThe Origin House deal along with VidaCann are crucial to the future of Cresco Labs. The company only reported Q2 revenues of $29.9 million while pro-forma revenues were up at $52.7 million. The pending acquisitions already accounted for nearly 45% of the revenue stream counted on by the company and this Tryke deal adds another $17.5 million in quarterly revenues based on FY18 numbers.The company already has the Illinois market projected to reach annual sales in the $2 to $4 billion range with adult-use cannabis starting on January 1. In addition, Cresco Labs got regulatory approval for an acquisition of Valley Agriceuticals, LLC providing for access into New York. Along with a license in Michigan, Cresco Labs is poised for substantial growth with or without all of these pending acquisitions closing.Consensus VerdictWith 7 'Buy' ratings in the last three months, the word on the Street is that Cresco Labs is a ‘Strong Buy'. Its $17.41 average price target suggests about 150% upside potential. (See Cresco Labs's price targets and analyst ratings on TipRanks)TakeawayThe key investor takeaway is that regulatory uncertainty is a big factor in the weakness of Cresco Labs. For investors that believe in the sector, Cresco Labs now offers the potential for a $1+ billion business trading with a fully diluted market valuation of only $2 billion. Unfortunately, the stock is likely to trade weak until progress is made on all of these pending deals.Disclosure: No position.

  • Business Wire

    Cresco Labs and Origin House Announce Substantial Compliance with HSR Second Request

    Cresco Labs Inc. (“Cresco Labs”) (CL.CN) (CRLBF) and CannaRoyalty Corp. d/b/a Origin House (“Origin House” and together with Cresco Labs, the “Companies” – CSE: OH, OTCQX: ORHOF), both announced today that, effective September 16, 2019, they have each submitted certifications of substantial compliance with the request for additional information (“Second Request”) from the United States Department of Justice Antitrust Division (the “DOJ”) in connection with Origin House’s and Cresco Labs’ notification to U.S. antitrust authorities pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”), as amended, in respect of Cresco Labs’ pending acquisition of Origin House (the “Transaction”).

  • Benzinga

    Cresco Labs Reaches Utah; Expands In Nevada, Arizona

    With this agreement Cresco Labs will expand its presence acquiring six prime Reef Dispensary locations in Nevada and Arizona, licensed cultivation and process capacity in Phoenix and Las Vegas, and it will enter the Utah market, the company said. Entering the Utah market will mark the company’s access to a 12th state, and the transaction will also make the company one of the top 3 cannabis operators in Nevada, and it will increase its market share in Arizona by 300%, as per the press release. Cresco Labs said the purchase price is set to around $282.4 million, which will consist of the company’s shares (around $227.5 million) and cash (around $55 million).

  • Business Wire

    Cresco Labs to Acquire Tryke Including the Reef Dispensary Portfolio – Consistent With Stated Plan to Establish Market Leading Positions in Both Nevada and Arizona and Build Brand and Wholesale Capabilities

    Tryke generated US$70.4 million in Revenue and US$24.6 million in EBITDA in fiscal 20181, making it one of the highest grossing and most profitable private cannabis companies in the U.S. market. Arizona is one of the largest and fastest growing medical-only markets with estimated 2019 sales of up to US$760 million 2 . Tryke has established six of the best-positioned retail locations in Nevada and Arizona, including the iconic Reef Dispensary located adjacent to the Las Vegas Strip and five additional operating locations in North Las Vegas, Sparks and Phoenix, AZ.

  • CNW Group

    Cresco Labs to Acquire Tryke Companies Including the Reef Dispensary Portfolio - Consistent With Stated Plan to Establish Market Leading Positions in Both Nevada and Arizona and Build Brand and Wholesale Capabilities

    Tryke generated US$70.4 million in Revenue and US$24.6 million in EBITDA in fiscal 20181, making it one of the highest grossing and most profitable private cannabis companies in the U.S. market. Arizona is one of the largest and fastest growing medical-only markets with estimated 2019 sales of up to US$760 million 2. Tryke has established six of the best-positioned retail locations in Nevada and Arizona , including the iconic Reef Dispensary located adjacent to the Las Vegas Strip –  which has produced over US$65 million in revenue since 2015 – and five additional operating locations in North Las Vegas , Sparks and Phoenix, AZ.

  • Wall Street's first cannabis analyst names her top US marijuana stocks
    Yahoo Finance

    Wall Street's first cannabis analyst names her top US marijuana stocks

    Cowen analyst Vivian Azer just crowned a new U.S. cannabis company with her strongest conviction Outperform.

  • MarketWatch

    Cowen is bullish marijuana companies with CPG model, bearish on MedMen given retail reliance

    Cowen analyst Vivien Azer initiated coverage Friday of five multi-state cannabis operators, saying she's bullish on those that rely on the consumer packaged goods model given the higher margins, especially relative to those relying on the retail model. Azer started Green Thumb Industries Inc. at outperform with a stock price target of $18.50, Curaleaf Holdings Inc. at outperform with a $10.50 target, and Cresco Labs Inc. at outperform with a $14 target. "We believe that the greatest shareholder value will be created through businesses that emulate a traditional CPG finished goods model, given its superior margin structure," Azer wrote in a note to clients. Meanwhile, Azer started MedMen Enterprises Inc. at underperform with a $1.50 price target. "[MedMen] is the clear leader in the [California] market, with a distinguished brand, reflecting an attractive retail concept," Azer wrote. "However, to us, retail is less attractive than wholesale. And, an over-reliance on retail revenues today, coupled with excessive spending and notable management turnover, make this a'show-me' story." Azer also started Acreage Holdings Inc. at market perform with a $9 target, saying consolidation a of a "disparate network of dispensaries" and launching a "nascent brand strategy" could prove challenging. The ETFMG Alternative Harvest ETF was up 0.4% in afternoon trading, but has lost 28.7% over the past three months, while the S&P 500 has gained 3.5% in three months.

  • Benzinga

    2019: A Year Of Cannabis M&A Deals

    Anyone who closely follows the cannabis industry knows that it is experiencing unrivaled growth. The year is set to end with a 31.7% increase in annual legal cannabis sales, bolstered by new regulation, ...

  • These U.S. Pot Stocks Are a Bargain, According to This 69-Year-Old Investment Bank
    Motley Fool

    These U.S. Pot Stocks Are a Bargain, According to This 69-Year-Old Investment Bank

    Three vertically integrated multistate operators look attractive to Canaccord Genuity.

  • These 3 States Will Begin Selling Recreational Pot Fairly Soon
    Motley Fool

    These 3 States Will Begin Selling Recreational Pot Fairly Soon

    Two of these three states should be billion-dollar cannabis markets by 2024.

  • Benzinga

    New Report Puts North American Cannabis Market At $47.3B By 2024

    Market research and data analytics firm Prohibition Partners has released its first North American Cannabis Report. In the 134-page paper, the firm analyzes the current state of the cannabis industry in Canada and the United States to draw key insights into the industry’s future in the region. The firm is estimating that by 2024, the continent's cannabis market will be worth $47.3 Billion.

  • Why Cresco Labs Could Be an Underrated Stock to Buy Today
    Motley Fool

    Why Cresco Labs Could Be an Underrated Stock to Buy Today

    Despite the industry's latest woes, there are still some good deals for cannabis investors.

  • TipRanks

    Seaport Sees a Sea Change in Marijuana Stock Valuations

    Just three months ago, Seaport analyst Brett Hundley was rolling back price targets on Canadian cannabis stocks, cutting forecasts for both sales and EBITDA left and right -- and Hundley was right to do so. Since the analyst began slashing targets, shares of Aphria (APHA) and Hexo (HEXO) (two subjects of the analyst's ire in June) have fallen 10% and 35%, respectively. More broadly (and over a longer time horizon) the Horizons US Marijuana Index ETF has declined 39% from April to today -- against a broader S&P 500 performance that's been basically flat.And yet, there comes a day that marijuana stock prices get too cheap to ignore, and that day, apparently, was Labor Day 2019.Seaport Announces a Labor Day SaleIn a report just out entitled "Labor Day Sale", Hundley argues that after the sell-off, it's now "time to buy cannabis stocks" again. His reason:"Quality cannabis names" are trading at "2020 price-to-sales multiples near 3.0x-4.0x, alongside EV multiples of 7.5x-10.5x against 2020/21 EBITDA expectations." In the analyst's opinion, these valuations have been depressed for several good reasons, including "disappointing and frustrating regulatory developments, delayed profitability expectations, specific compliance/credibility issues, and founder/management upheaval."And yet, Hundley foresees a "potential for forward regulatory improvements/updates and widening access to capital" that could result in higher valuations going forward. And he further argues that "the [marijuana] space is profitable" already -- albeit only profitable from the perspective of "EBITDA," which considers earnings but not the interest, taxes, depreciation, and amortization that generally come along with (and subtract from) them.Given this continued absence of real profitability, though, are any of these stocks really bargains, even down 39% on average?3 'Quality Cannabis Names' to ConsiderHundley notes that the valuations on his alleged "quality cannabis names" look attractive when compared to "biotech/pharma" stocks trading "6.0x+ 2020 sales expectations and 15.0x-25.0x 2020/21 EBITDA expectations." But which ones exactly? Let's take a closer look.Canopy Growth (CGC) for example, probably the best-known Canadian cannabis stock (and certainly the most expensive at $8.9 billion in market capitalization), currently sells for 19 times the $467 million in sales it's expected to produce in 2020. Aurora Cannabis (ACB), the next-biggest player in the industry at $5.9 billion in market cap, costs more than 11 times the $516 million in sales that analysts project for it in 2020. And Cronos Group (CRON), No. 3 in the industry at $3.9 billion in market cap, costs a staggering 23.6 times forward sales!In fact, to get anywhere close to his promised "3.0x-4.0x" sales valuations, Hundley has to scrape pretty far down into the barrel, coming up with just one example from his own coverage list: Green Thumb Industries (GTBIF), which he says at $1.6 billion in market cap costs 3x fiscal 2020 projected sales. Granted, the analyst says there are other names down in that barrel as well, if you're willing to look for them -- Cresco (CRLBF) for one, and Trulieve (TCNNF) for another.But if these are the kind of "quality cannabis names" Hundley is urging investors to look for, it bears asking: If they're so great, why hasn't he bothered to cover Cresco and Trulieve before?The answer could be as simple as this: Because they aren't.Visit TipRanks’ Trending Stocks page, and find out what companies Wall Street’s top analysts are looking at now.

  • This Marijuana Stock Is Poised for a Big Rally
    TipRanks

    This Marijuana Stock Is Poised for a Big Rally

    Origin House (ORHOF) has been put on the cannabis map in a big way because of the attempt by Cresco Labs (CRLBF) to acquire the company. This has unfortunately taken the focus off of the actual performance of the company, as uncertainty concerning the deal being approved weighs on the share price of Origin House for now.The most recent earnings report was a good one for the company, and when coupled with a recent decision by Weedmaps which will result in a significant reduction in cannabis sales in the California cannabis market, Origin House is positioned to benefit greatly from that action.Cresco Labs acquisition not a done dealSome investors consider the attempt by Cresco Labs as a done deal, as does management, which has stated it doesn't believe it'll fail in getting the deal done.The C$1.1 billion offer by Cresco Labs appeared to be a sure thing in the early stage of the process, but it wasn't long afterward that the Department of Justice requested more information concerning the proposed deal based upon the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Why that matters is these types of requests are related to issues related to reducing competition. Even though it's being spun as not much more than a formality, in fact it could derail the deal and leave both companies as they were before the offer was made.This is why looking at the fundamentals of Origin House is important, as the assumption should be made by investors that the deal won't be allowed to go through. After all, some paid a premium price for the company based upon the idea it was going to go forward.I'm not suggesting it isn't going to be approved, as I think it has more than a 50 percent chance of being given the go ahead. But the company would take a hit if it is stopped, and investors should be prepared for the company to stand on its own merits either way.With that in mind, there's a lot to like about the future prospects of Origin House, whether it's acquired by Cresco Labs or not.California cannabis market has been a messA fallout from the policies associated with the California cannabis sector has resulted in a lot of customers going back to the black market as their source of supply.The two major reasons for this are leaving up to individual jurisdictions concerning what is allowed, and second, the enormous taxes levied against cannabis sales.Taking into account there are 58 counties and 482 incorporated cities and towns in California, it's not surprising to see the disastrous consequences of each one deciding on the guidelines and laws associated with cannabis.Not only are there different rules from city to city, but a county may have one set of rules, while the individual cities in the county have a different set of rules. It also means in many jurisdictions pot remains effectively prohibited. That's important because many people have chosen to go back to the black market for their recreational pot supply.Changing practices at Weedmaps is going to change this situation around.As for the combination of state, local, and excise taxes, that could in a number of cases surpass the 40 percent mark, dependent upon the tax burden in each municipality. Not only has that pushed users toward the black market, but also to Nevada, where overall cannabis costs are much lower.Weedmaps Weedmaps is an Internet directory that allows marijuana dispensaries and users to connect with one another.Until recently Weedmaps has allowed legal and illegal operators to advertise on the platform. About a week ago Weedmaps said that starting in the latter part of 2019, it was no longer going to allow illegal or unlicensed dispensaries on the platform. Weedmaps stated it will help unlicensed operators to go through the process of reaching compliance, but that will take some time to work itself out.Upon hearing of the decision, some have suggested it could result in as much as 50 percent of illegal sales to be slashed in California. This is a potentially huge catalyst for Origin House.The benefit to Origin HouseThe strength of Origin House in California is the distribution assets it owns. All legal cannabis products sold in California must be handled via licensed distributors.Only a distributor can transport cannabis products in the state, and they are required to ensure all of their labeling and packaging is compliant with guidelines. They also act as the tax collector for all sales in the state.So when Weedmaps announced it was going stop allowing unlicensed businesses on its platform, it means a huge swath of the black market competition will lose business to the benefit of Origin House and other distributors.Since Origin House has acquired a number of important California distribution licenses and companies in California, it is positioned to take advantage of this major catalyst, which will drive revenue up in the quarters ahead.With so much fragmentation in the California cannabis sector, this is going to be a welcome change to end-users in my opinion, and it will be a major catalysts for cannabis distributors in the state.C$12 Price TargetDown by nearly 40% from its April highs, Origin House stock rides the rollercoaster of investor sentiment. But the good news for shareholders is that this sentiment may take a turn for the better. 4-star analyst Matt Bottomley is advising his clients to buy the stock, and he believes it could hit C$12 within a year. For perspective, Origin House's stock closed at C$7.74 today, so this implies upside of about 55%. (To watch Bottomley's track record, click here)ConclusionWhile the focus on many investors has been on the potential acquisition of Origin House by Cresco Labs, it has quietly went about generating strong sales, which are going to continue to improve going forward as the huge black market in California shrinks to the benefit of Origin House.For those reasons, even if the acquisition is not allowed to go forward, the future of Origin House is very bright.At its current share price level, there isn't a lot of support remaining from the announced deal. If it doesn't go forward, Origin House will take a hit, but I see it rapidly returning to where it is at now based upon the potential associated with new sales growth coming in the latter part of 2019 and into 2020.However it plays out, I think Origin House is going to make shareholders happy.Visit TipRanks’ Trending Stocks page, and find out what companies Wall Street’s top analysts are looking at now.Disclosure: No position

  • Earnings Forecasts for U.S. Pot Stocks Are Starting to Crumble
    Motley Fool

    Earnings Forecasts for U.S. Pot Stocks Are Starting to Crumble

    Is it time for investors to head for the exit?

  • Origin House's Revenue Skyrockets as the California Cannabis Market Gains Momentum
    Motley Fool

    Origin House's Revenue Skyrockets as the California Cannabis Market Gains Momentum

    The marijuana company delivered record high results thanks to strong California operations and added revenue from its Canadian business.

  • 3 Top Cannabis Stocks to Buy in September
    Motley Fool

    3 Top Cannabis Stocks to Buy in September

    These marijuana stocks look like winners for investors with long-term perspectives.

  • The Decline of Cresco Labs Stock Creates a Great Entry Point
    TipRanks

    The Decline of Cresco Labs Stock Creates a Great Entry Point

    The U.S. cannabis multi-state operator (MSO) sector isn’t getting a lot of respect lately despite a group of stocks building a strong future. A prime example is Cresco Labs (CRLBF) trading near multi-month lows following strong Q2 results. The stock is being overlooked as the market losses focus during the dull summer months while Cresco Labs builds a solid position in 2020.Strong Q2The U.S. MSOs have multiple paths for growth. The companies can buildout existing licenses in states with approved cannabis and enter new states once cannabis is approved. A prime example is the approval of adult-use cannabis in Illinois.The actual financials are messy and a prime reason why the stock has hit a period of weakness. During Q2, Cresco Labs saw Q2 revenues surge 42% QoQ to $29.9 million. The issue here is that pro-forma revenues were $52.7 million for 55% sequential growth.Investors have to decide on whether to value the stock based on actual or pro-forma revenues. The market appears to be passing on the stock due to the regulatory approval delays considering the stock reached a high in April following the announcement of the acquisitions.Cresco Labs has a market value of $1.1 billion or something slightly below $2.0 billion on a fully diluted basis with the closing of both Origin House (ORHOF) and VidaCann. The deals were expected to close by June and now apparently won’t close until later this year.The company generated a Q2 adjusted EBITDA of $2.3 million and Cresco Labs has working capital of $128.7 million with zero debt so the company doesn’t need the deals to survive and thrive. Unfortunately for shareholders, the market sees the sector as needing these large deals to close and the regulatory uncertainty has investors sitting on the sidelines.Part of the problem could be the lack of seeing the full financials of companies that will contribute 45% of current revenues. The integration is crucial to the success and a couple of decent deals at the same time could be tricky for an unproven management team.The FutureWithout these deals closing, Cresco Labs has the Illinois market going from 5 dispensaries to 10 stores as the adult-use market opens up on January 1. The Illinois market is targeted at $2 to $4 billion in sales and alone matches some of the global cannabis markets that Canadian LPs are chasing. Cresco Labs doesn’t even have to chase this market as it just opens up for the company that will surely improve the profits of the U.S. MSOs over the Canadian peers.In addition, the company has a license in Michigan and regulatory approval to enterNew York via the acquisition of Valley Agriceuticals, LLC. Cresco Labs is poised to expand into Michigan, New York and Massachusetts with or without closing the acquisitions of Origin House and VidaCann.TakeawayThe key investor takeaway is that regulatory uncertainty is a big factor in the weakness of Cresco Labs. The company is positioned for substantial growth one way or another allowing investors to comfortably take advantage of the current stock weakness.At only $8, Cresco Labs now offers the potential for a $1+ billion business trading with a fully diluted market valuation below $2 billion.Visit TipRanks’ Trending Stocks page, and find out what companies Wall Street’s top analysts are looking at now.

  • Marijuana Stock Cresco Labs' Revenue Soars 253%
    Motley Fool

    Marijuana Stock Cresco Labs' Revenue Soars 253%

    The cannabis company's sales are expanding at a torrid clip.

  • Benzinga

    Cresco Labs Reports Q2 Earnings: 'We Delivered An Outstanding Quarter'

    Cresco Labs disclosed a net loss of $3.9 million for the quarter, compared to a net income of $1.6 million in the same quarter last year. “We delivered an outstanding quarter that reflects the leading positions we have established in some of the most attractive markets in the cannabis industry,” CEO Charlie Bachtell said in a statement.

  • What You'll Want to Know About Cresco Labs' Q2 Results
    Motley Fool

    What You'll Want to Know About Cresco Labs' Q2 Results

    The U.S. cannabis operator saw sales skyrocket. But its spending soared, too.

  • Business Wire

    Cresco Labs Announces Increased Profitability in Second Quarter 2019 With Revenue Growth of 253% Year-Over-Year and 42% Quarter-Over-Quarter

    Conference Call with Investors and Analysts to be Held at 5:00 p.m. Eastern Time Today

  • Why Is Cresco Labs Tanking ahead of Its Q2 Results?
    Market Realist

    Why Is Cresco Labs Tanking ahead of Its Q2 Results?

    Cresco Labs (CRLBF) is all set to report its second-quarter results after the market closes today. Cresco stock tanked 6.9% yesterday.

  • Why Cresco Labs Stock Still Looks Like a Good Long-Term Bet
    TipRanks

    Why Cresco Labs Stock Still Looks Like a Good Long-Term Bet

    Cresco Labs (CRLBF) shares have risen nearly 13% this month, at a time when much of the cannabis industry has been under pressure from investors abandoning speculative markets and some bad news coming from the sector concerning growing pot in unlicensed facilities.This is interesting because Cresco Labs had lagged most of its peers in 2019, until it announced the news it had made an offer to acquire Origin House for $823 million. That would give it a big footprint in California if it gains regulatory approval.It also received regulatory approval to go ahead with its acquisition of Gloucester Street Capital (parent of Valley Agriceuticals), which will close near the end of August. This gives them a footprint in the fourth largest U.S. market of New York.Combined with its home market of Illinois and its build-out in other states, Cresco Labs has been gaining a lot of momentum leading up to its earnings report this evening.Valley Agriceuticals dealWith momentum favoring Cresco Labs at this time, it was a nice boost to get the Valley Agriceuticals acquisition deal approved of by regulators a short time before its earnings report was scheduled.The primary significance of the deal is it receives one of the 10 cannabis business licenses awarded by the New York State Department of Health. Individual licenses allow a company to operate one cultivation facility and four dispensaries in the state of New York.CEO of Cresco Labs, Charles Bachtell, said this:> As the holder of one of only 10 vertically integrated businesses licenses in New York, we believe that Cresco Labs will make a significant impact in this large and influential market that is projected to grow to $500 million by 2022, according to Arcview/BDS Analytics.At this time Valley Agriceuticals has two dispensaries operational, one in Bardonia and another in New Hartford, and should have the other two opened in Brooklyn and Long Island within a couple of weeks. That means it won't be long before the company gets a boost to its top and bottom lines from the acquisition.Investors need to know that this doesn't include recreational pot because New York didn't legalize it when it came up for a vote. So while it may not generate the immediate revenue that would accompany adult-use pot, it does provide an improvement to its margins and earnings as a result of medical cannabis salesTo get an idea of the potential, as of this writing New York has 105,000 medical cannabis patients, and it could reach over five times more patients than that if it reaches about 3 percent of the New York population. In Arizona, medical cannabis penetration is 2.9 percent.Origin House is the major catalyst behind share price boostMuch of the recent climb in share price for Cresco Labs is associated with its bid to acquire Origin House. Why it matters is it would give Cresco a huge footprint in the largest cannabis market in the world.Origin House is one of only several companies that hold cannabis distribution licenses in California. Consequently, Cresco will be able to sell its products to over 500 dispensaries in the state. It can't be overestimated how much this would increase the performance of Cresco over the short and long term.The caveat is the companies haven't yet received approval from regulators after they were asked to provide more information. While that's not unprecedented, it is unusual.It appears the market is still considering it a done deal, which is why the share price has skyrocketed so quickly.It wouldn't surprise me to see it climb, but as its earnings day approaches, it may be wise to take some profits off the table. I think a lot of the upside has been priced in, and if there is any disappointment in the earnings report, its share price will quickly pull back.Further out, if the deal is not approved, the share price is going to get crushed. Even so, the company is building a solid base to grow from, and even under that scenario it will recapture some of that once the market settles down.If the deal is approved, it will of course get a temporary big upward move in the share price in response to the positive catalyst.Other catalystsCresco Labs has other growth initiatives being deployed at this time, including the announcement it's going to open up 50 stores in 11 states.Its first Sunnyside dispensary will open in Philadelphia in November. with other stores scheduled to be open in Arizona, Florida, Illinois, Massachusetts, and Michigan, among other states. Illinois should be important to Cresco once it legalizes recreational pot in January.One weakness of Cresco has been the low number of open dispensaries it has had. That will change once these deals are consummated and adds more stores organically.Another strong catalyst has been the outlook analysts covering the stock have. Three of those covering it have a “strong buy” rating on the stock, and four others have a “buy” rating.Recently Matthew Pallotta of Echelon Wealth Partners initiated coverage on Cresco Labs, starting it off with a “Speculative Buy” rating.Some of the positive outlook is related to the company proving it can take significant market share in some markets, including Illinois (28 percent) and Pennsylvania (30 percent), according to the company.Since it has done so well in those states it is well established in, the assumption is it should be able to successfully scale out to other markets as well.In the early days of recreational pot legalization in Illinois, Cresco could capture more market share because of its three production facilities and as many as ten licensed recreational pot dispensaries.With all the recent bullish outlook concerning Cresco, it should taken into account that it still lags behind where it had traded not too long ago.ConclusionCresco Labs hasn't impressed the market so far in 2019, as it has had only a small number of dispensaries in operation in contrast to some of its major competitors, but that is quickly changing.While the company is growing in many ways, the fact is its recent increase in share price is based primarily upon the assumption it will be allowed to proceed with its acquisition of Origin House.If that does get approved, it will position Cresco Labs as one of the largest generators of revenue in the U.S., and in fact, the world. It, combined with the other catalysts mentioned above, will drive the share price of the company much higher, and it may even be able to sustain it for some time if it releases some impressive earnings reports.I like Cresco, but it really is dependent upon the Origin House deal being approved. Since it's not guaranteed, it will be held back some until that is made clear.Even if it doesn't get approved, there are still a lot of catalysts to propel the company to long-term growth, albeit at a much more modest pace than is expected at this time.To get TipRanks’ stock analysis report on Cresco Labs, click here